41 results about "Chemotherapy effects" patented technology

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses an EGFR (epidermal growth factor receptor) targeted nano-drug carrier and a preparation method thereof, the EGFR targeted nano-drug carrier comprises drug-loading nanoparticles, an erythrocyte membrane coating the drug-loading nanoparticles and GE11 peptide connected to the erythrocyte membrane, and the drug-loading nanoparticles are formed by connecting tannic acid, ellagic acid and 1, 4-phenyldiboronic acid through boric acid ester bonds. The EGFR targeted nano-drug carrier disclosed by the invention can be enriched at an EGFR overexpressed tumor site in a targeted manner, and can be effectively prevented from being cleared by an immune system, and the drug loaded by the drug-loaded nanoparticles is released in a high-active oxygen environment, so that the treatment effect on tumors can be improved, and the toxic and side effects on normal tissues can be reduced; and photothermal therapy and chemotherapy effects can be simultaneously generated under NIR illumination, and the anticancer efficiency can be remarkably improved through the synergistic effect of the photothermal therapy and the chemotherapy.

The invention discloses a graphene quantum dot material as well as a preparation method and application thereof, and belongs to the technical field of biomedical materials. The preparation method comprises the following steps: S1, carrying out hydrothermal reaction on a mixed solution of mesoporous SiO2 and a carbon source to obtain a product I; s2, the product I and a fluoride solution are mixed to remove SiO2, and a product II is obtained; and S3, refining the product II to obtain the graphene quantum dot material. The carbon source is selected from at least one of triammonium citrate, diammonium hydrogen citrate, citric acid, folic acid, urea, thiourea and dicyanodiamine; the fluoride is selected from ammonium bifluoride and / or hydrogen fluoride. The particle size of the graphene quantum dot material provided by the invention is 15-30nm, the distribution is controllable, and the raw materials are easy to obtain; the prepared platinum nanoparticle / graphene quantum dot composite nanomaterial is high in solubility, stable in physical and chemical properties and remarkable in chemotherapy effect.

The invention discloses a grifola frondosa-derived exosome-like nano-vesicle as well as an extraction method and application thereof. The extraction method comprises the following steps: cutting pilei and stipes of grifola frondosa, and grinding with a proper amount of cold PBS to prepare grifola frondosa bacterial juice; the grifola frondosa juice is centrifuged at 500 g-1, 000 g, sediment is discarded, the obtained supernatant is centrifuged at 2,000 g-3,000 g, sediment is discarded, the obtained supernatant is centrifuged at 10,000 g-12,000 g, sediment is discarded, the obtained supernatant is filtered, and the pretreated grifola frondosa juice is obtained; and centrifuging the pretreated grifola frondosa juice at 30,000-100,000 g for 30 minutes to 4 hours, and resuspending by using PBS (Phosphate Buffer Solution), so as to obtain the grifola frondosa-derived exosome-like nano-vesicles. The invention develops a new thought for the mechanism of cancer inhibition, chemotherapy effect enhancement and flora regulation of the grifola frondosa, and lays a foundation for application of the grifola frondosa in development of products such as related foods, functional foods, health foods, medicines and gel-loaded medicines.

The invention relates to a hybrid nano assembly for dual synergistic chemotherapy as well as a preparation method and application of the hybrid nano assembly, and belongs to the technical field of pharmaceutical preparations. The invention relates to a hybrid nano assembly for dual synergistic chemotherapy, which is formed by co-assembling a cabazitaxel prodrug and gossypol under hydrophobic action and hydrogen bond driving, and is modified by adopting a PEG (Polyethylene Glycol) modifier, the molar ratio of the cabazitaxel prodrug to the gossypol is 1: (1-7), and the ratio of the total mass of the cabazitaxel prodrug and the gossypol to the mass of the PEG modifier is 4: 1. A cabazitaxel prodrug and a sensitizer gossypol are co-assembled to obtain a hybrid nano assembly, the hybrid nano assembly is oxygenated to obtain the oxygen-carrying preparation, the nano assembly and the oxygen-carrying preparation are simple and convenient to prepare and high in drug loading efficiency, and efficient co-loading of drugs can be achieved; meanwhile, the curative effect of chemotherapy can be enhanced through dual mechanisms of relieving tumor hypoxia and promoting tumor apoptosis, and the pharmaceutical composition has a good clinical application prospect.

The invention discloses a nano preparation for natural product synergistic chemotherapy as well as a preparation method and application of the nano preparation, nanoparticles are formed by self-assembly of an SN38 prodrug sensitive to redox and galangin in a carrier-free manner, and can also be co-assembled nanoparticles modified by polyethylene glycol or entrapped with hydrophobic fluorescent molecules. According to the SN38 prodrug, a fluorene methanol side chain is coupled to an SN38 molecule through a redox-sensitive disulfide bond, so that a prodrug structure with a responsive release characteristic is constructed. The construction of the nano system not only significantly reduces the off-target toxicity of SN38 and improves the tolerance dose of SN38, but also enhances the SN38-mediated chemotherapy effect by the sensibilization effect of galangin, significantly improves the treatment efficiency, and realizes high-efficiency and low-toxicity cancer treatment. The invention provides a novel and synergistic prodrug nano drug delivery platform, and a new strategy is provided for precise treatment of refractory tumors.

This invention discloses a multifunctional tumor-targeted cryotherapy nanoplatform and its applications, belonging to the field of nanobiomedicine technology. The multifunctional tumor-targeted cryotherapy nanoplatform of this invention uses two-dimensional Ti3C2 nanomaterials as a carrier, loaded with indocyanine green as a photosensitizer, surface-modified with polydopamine to improve stability, and loaded with gambogeylic acid as an anti-tumor drug and a heat shock protein inhibitor. It is covalently coupled with nucleic acid aptamers that can recognize cell surface-specific proteins. The multifunctional tumor-targeted cryotherapy nanoplatform has small particle size, high dispersion, and good biocompatibility, and exhibits excellent photothermal conversion ability, photodynamic therapy effect, and chemotherapy effect in tumor-targeted therapy. It can effectively induce tumor cell apoptosis under relatively low temperature conditions, significantly reducing the damage of high temperature to surrounding healthy tissues. It also has the ability to specifically recognize tumor lesions, achieving high enrichment at the tumor site and enhancing the therapeutic effect.

The application discloses Lactobacillus reuteri and application thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, and relates to the technical field of biological medicine. The application provides application of Lactobacillus reuteri and / or a metabolite thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, wherein the Lactobacillus reuteri is Lactobacillus reuteri (HG001). Limosilactobacillus reuteri The Lactobacillus reuteri is separated from feces of healthy people and used for preparation of the medicine for treating diffuse large B-cell lymphoma, and it is found that the Lactobacillus reuteri is confirmed as a probiotic strain for enhancing the chemotherapy effect of diffuse large B-cell lymphoma and can improve side effects caused by cyclophosphamide treatment of diffuse large B-cell lymphoma; and the Lactobacillus reuteri and the cyclophosphamide have a synergistic effect in treatment of diffuse large B-cell lymphoma.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

The application discloses a polymer vesicle-stabilized drug-iodized oil emulsion and a preparation method and application thereof, to realize safe and efficient transarterial chemoembolization (TACE) treatment of hepatocellular carcinoma in situ. The drug-iodized oil emulsion system has the following advantages: simple preparation, convenient size adjustment, excellent stability, near-zero order and sustained controllable drug release rate, low blood drug concentration after transarterial embolization, and the retention time and retention amount of the drug in the liver are superior to those of free drug-iodized oil emulsion used in clinical treatment, the tumor can be completely eradicated, angiogenesis can be effectively inhibited, and adverse reactions can be reduced. In general, the polymer vesicle-stabilized drug-iodized oil emulsion has the advantages of high stability and sustained controllable drug release, and can greatly improve the embolization chemotherapy effect of hepatocellular carcinoma, and provide a safe and efficient TACE strategy.

The present invention provides a kind of Chinese medicine preparation for preventing and treating myelosuppression after chemotherapy, relates to the field of Chinese medicine pharmacy, the Chinese medicine preparation is made of 1-15 parts of antler glue, 1-10 parts of astragalus, 1-10 parts of cinnamon twig, 1-10 parts of notoginseng, 1-10 parts of immature bitter orange, 1-10 parts of rhizoma anemarrhenae, 1-10 parts of phellodendron, and the Chinese medicine preparation of the present invention has the effects such as replenishing qi and blood, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain. The Chinese medicine preparation of the present invention can reverse the myelosuppression caused by 5-FU chemotherapy by improving the peripheral blood count and bone marrow pathological damage of chemotherapy mice. In addition, the Chinese medicine preparation of the present invention can improve the 5-FU chemotherapy effect by increasing the 5-FU tumor inhibition rate, suppressing tumor weight, tumor volume and promoting tumor tissue necrosis. The Chinese medicine preparation of the present invention and the chemotherapy drug 5-FU are used in combination to have a certain synergistic and toxicity-reducing effect, and are expected to be developed as a medicine for preventing and treating myelosuppression after chemotherapy.

The invention belongs to the technical field of biological medicine, and particularly relates to application of REXO4 interference polypeptide in tumor treatment. It is found for the first time that the REXO4 interference polypeptide can inhibit breast cancer tumor cell proliferation, promote chemotherapy drug-induced DNA damage and improve the breast cancer chemotherapy effect, in addition, through combination of the REXO4 interference polypeptide and Olaparib, the remarkable synergistic anti-tumor effect can be shown, and the effect is better than that of single medication. The invention also finds that the REXO4 interference polypeptide can reverse the drug resistance of breast cancer to chemotherapeutic drugs, and a brand new solution is provided for overcoming the drug resistance of PARP inhibitors.

The utility model discloses a tumor local thermochemotherapy device which comprises a support and a thermochemotherapy device body, the thermochemotherapy device body is fixedly connected to the front end of the support, the front end of the support is fixedly connected with a connecting plate, the front end of the connecting plate is movably connected with a connecting column, the outer side of the connecting column is movably connected with two sets of fixing clamps, and the fixing clamps are fixedly connected with the support. And the two groups of fixing clamps are mutually symmetrical. According to the tumor local thermochemotherapy device, the chemotherapy device can be conveniently transferred, and meanwhile, the chemotherapy device can be fixed to a sickbed, so that the situation that the chemotherapy effect is affected due to deviation in the chemotherapy process is avoided.

The present invention belongs to the field of pharmaceutical chemistry technology, and specifically relates to a near-infrared light-releasing binuclear ruthenium complex, its preparation, and its application in combating drug resistance in non-small cell lung cancer. The binuclear ruthenium complex disclosed in the present invention has the structural formula shown below. The complex has a strong photochemotherapy effect on cisplatin-resistant human non-small cell lung cancer cell lines. Under light conditions, it has a strong growth and proliferation inhibition ability (IC 50 The phototoxicity of the metallo-photosensitive material was 0.22 μM, while in the dark, its cytotoxicity was only 75.6 μM, and the phototherapy index (PI) was as high as 343, which is of great significance for the study of metallo-medicines for anti-drug-resistant tumors. It is expected to be used to prepare anti-tumor photoactivated drugs or drugs for anti-proliferation of cisplatin-resistant strains of human non-small cell lung cancer, and even anti-tumor metal photosensitizers.

The invention provides a pharmaceutical composition and application thereof in preparation of medicines for treating ovarian cancer, and the pharmaceutical composition is prepared from the following components in parts by weight: 5-20 parts of cortex phellodendri, 5-20 parts of rhizoma atractylodis, 5-20 parts of radix achyranthis bidentatae, 5-20 parts of oldenlandia diffusa, 5-20 parts of radix trichosanthis, 5-20 parts of cassia twig, 20-40 parts of radix astragali and 20-40 parts of semen coicis. The pharmaceutical composition provided by the invention is suitable for ovarian cancer postoperative combined chemotherapy, and can significantly reduce the incidence rate of adverse reactions of chemotherapy, improve the chemotherapy effect and compliance, and reduce the toxic and side effects of chemotherapy drugs.

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

The invention discloses a breast cancer neoadjuvant chemotherapy result evaluation system, and belongs to the field of medical diagnosis. The breast cancer neoadjuvant chemotherapy result evaluation system comprises a data collection module, a data processing module, a tumor analysis module and a tumor grading module. The problem that stable and reliable chemotherapy curative effect evaluation is lacked in the prior art is solved, the image data before and after chemotherapy are collected and preprocessed, and then the tumor area characteristics in the image data are extracted by using the convolutional neural network model, so that deep analysis and diagnosis of tumors are realized, and the chemotherapy curative effect evaluation accuracy is improved. The characteristics of image data before and after chemotherapy are compared, and the size of the tumor is calculated by utilizing the mahalanobis distance, so that the change rule of the tumor before and after chemotherapy is further disclosed, a basis is provided for formulating a reasonable treatment scheme, the chemotherapy effect is divided into different grades according to an analysis result, and the treatment efficiency is improved. And corresponding treatment schemes are formulated according to different grades so as to improve the treatment effect.

The invention discloses a precise tumor chemoradiotherapy drug delivery device, which relates to the technical field of medical instruments, and comprises an injection host and a high-precision peristaltic pump mounted in the injection host, and further comprises a drug storage mechanism, a movable loosening and clamping assembly and a leakage detection assembly. During use, three independent cabin seats are arranged in the medicine storage mechanism, three medicine storage devices are clamped in the three independent cabin seats respectively, loading of three chemotherapeutic medicines can be completed in advance, frequent replacement of medicine storage cylinders is not needed, ordered infusion of the three medicines is achieved through opening and closing of a controllable communication valve in the gathering pipeline assembly, the treatment time is shortened, infusion continuity is improved, and the treatment efficiency is improved. In addition, in the medicine injection process, all the sensors detect medicine leakage, pipeline blockage, bubbles and medicine stock in real time, and precise medicine conveying is achieved. And a clamping mechanism is arranged in the module cabin body assembly, so that the medicine storage cylinder can be quickly disassembled and assembled, and the operation is simple and convenient.

The invention discloses a research method for promoting glioblastoma drug resistance by regulating YAP through P4HA1, and relates to the technical field of biology. The invention aims at researching whether P4HA1 has hydroxylation on YAP, so that the drug resistance of GBM to TMZ is influenced, and finally the proliferation condition of GBM is influenced, further exploring whether the treatment resistance of GBM can be improved after a P4HA1 inhibitor and a YAP inhibitor are combined with TMZ, and evaluating the possibility that P4HA1 and YAP are used as potential treatment targets by understanding the interaction between P4HA1 and YAP. According to the invention, a new treatment method capable of overcoming the drug resistance of GBM chemotherapy is found, the chemotherapy effect is improved, so that the prognosis of a patient is improved, the influence of P4HA1 and YAP on the drug sensitivity of GBM is innovatively evaluated, a new treatment strategy is provided for overcoming the clinical drug resistance problem, and potential signal channels and molecular targets are found.

The application relates to the field of medicine, in particular to the application of 4-hydroxyphenylacetic acid and irinotecan as cancer chemotherapy drugs. In view of the technical defects that the existing irinotecan chemotherapy hepatoprotective drugs have single action and may interfere with the chemotherapy effect, the application provides the application of 4-hydroxyphenylacetic acid and irinotecan in the preparation of cancer chemotherapy drugs. The application has the following advantages: 1. clear hepatoprotective effect: 4HPAA can significantly alleviate the liver fatty degeneration induced by irinotecan; 2. significant synergistic anti-tumor effect: the tumor inhibition effect of the combination of 4HPAA and irinotecan is significantly better than that of the single-drug group; 3. high safety; and 4. great clinical transformation potential.

This invention discloses a mesoporous silica nanoparticle, its preparation method, pharmaceutical composition, and applications. The nanoparticle is epoxy-modified, with its mesoporous channels loaded with polypeptide precursor molecules grafted onto chemotherapeutic drug molecules. Its outer layer is coated with an acid-sensitive polymer layer, enabling it to trigger drug release in the slightly acidic environment of the tumor. Furthermore, under the catalysis of highly expressed active enzymes within the nanoparticle, in-situ gelation occurs at the lesion site, thereby prolonging the retention time of the nanomedicine, improving the bioavailability of chemotherapeutic drugs, and enhancing the efficacy of chemotherapy.

The invention provides a spleen-tonifying and detoxifying traditional Chinese medicine composition as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises a formula A and a formula B. The traditional Chinese medicine composition has a comprehensive conditioning effect and can relieve chemotherapy side effects, improve intestinal flora distribution, promote intestinal health, enhance the chemotherapy effect and improve the disease control rate. Wherein the formula A focuses on tonifying spleen and regulating qi, and improving nausea, vomiting and other symptoms at the initial stage of chemotherapy, and the formula B is added with medicines for clearing away heat and toxic materials and promoting blood circulation to remove blood stasis on the basis, is suitable for patients with myelosuppression with cancer toxicity residue, and strengthens the effects of clearing away heat and toxic materials and removing stasis; the composition has a multi-target action mechanism, and through the combined action of multiple ways, the treatment effect is enhanced, and the side effect is reduced.

The present invention discloses an application of CCDC80, a small cell lung cancer chemotherapy resistance marker, and belongs to the field of biomedical technology. The present invention discovered for the first time that CCDC80 is significantly elevated in the plasma of patients with small cell lung cancer resistance. Overexpression of CCDC80 can reduce the sensitivity of SCLC cells to cisplatin and / or etoposide, while knocking down CCDC80 can enhance their chemotherapy sensitivity. CCDC80 promotes chemotherapy resistance by inhibiting cell apoptosis. Overexpression of CCDC80 can reduce the cleavage of Caspase3, Caspase7, and PARP, while knocking down CCDC80 can increase their cleavage levels. In vivo experiments showed that overexpression of CCDC80 can accelerate tumor growth and reduce the effect of chemotherapy, while knocking down CCDC80 can enhance the anti-tumor effect of chemotherapy, indicating that agents that inhibit CCDC80 expression can be used in combination with chemotherapy drugs to treat small cell lung cancer. The present invention provides new ideas for the treatment and research of SCLC resistance and has important clinical application value and economic value.

This invention discloses an artificial intelligence deep learning model for predicting the sensitivity of neoadjuvant chemotherapy in colorectal cancer, belonging to the field of colorectal cancer treatment prediction technology. Its key technical points include the following steps: S1, data collection; S2, patient grouping; S3, screening predictive factors; S4, artificial neural network modeling; and S5, model validation. This invention successfully screens common clinical indicators for predicting the sensitivity of neoadjuvant chemotherapy in colorectal cancer and constructs an artificial neural network risk prediction model. This model can be applied to clinical practice, providing predictions for the sensitivity of neoadjuvant chemotherapy in colorectal cancer, thereby assisting clinicians in achieving more accurate predictions of chemotherapy efficacy. This invention helps optimize clinical treatment strategies, promotes the development of individualized neoadjuvant therapy regimens for colorectal cancer, and provides new ideas and methods for precision medicine.

The invention belongs to the technical field of biological medicines, and discloses a polydopamine modified celecoxib and cisplatin loaded dual drug-loading microsphere, which takes a polydopamine modified polyvinyl alcohol microsphere as a carrier, and the surface of the microsphere is loaded with celecoxib and cisplatin. Celecoxib and cis-platinum loaded on the dual drug-loading microspheres prepared by the invention have a good synergistic effect, and can significantly inhibit the excessive growth of liver cancer in blood vessels; when being applied to the liver cancer TACE operation, the compound has relatively high safety and high operation success rate, and can remarkably inhibit tumor cell proliferation so as to improve the embolization chemotherapy effect. The invention also discloses a preparation method of the dual drug-loading microsphere.

The application aims to provide a preparation method and application of an oral engineering probiotic system for producing active substances in situ metabolism of tumors. First, the probiotic is cultured, the CES gene is inserted into a plasmid as a target gene, the plasmid containing the CES gene is transfected into a probiotic competent cell by a heat shock method, the engineering probiotic capable of continuously and stably expressing carboxylesterase is obtained, and the oral engineering probiotic system is prepared by coating the engineering probiotic with a natural high molecular material, mercapto hyaluronic acid. The preparation method is scientific and reasonable, raw materials are abundant, and the preparation is easy to produce. The preparation method enhances the chemotherapy effect of colorectal cancer and reduces the toxic side effects caused by the distribution of chemotherapy drugs in other tissues and organs, provides new technical support for the treatment of colorectal cancer, is an innovation in oral microecological preparation drugs, and has great economic and social benefits.

The invention discloses targeted nanoparticles for breast cancer treatment as well as preparation and application thereof, and belongs to the technical field of biological medicines. The invention provides a three-mode synergistic anti-tumor strategy of chemotherapy-photothermal therapy-Fenton-like reaction mediated ferroptosis for the first time. The targeting nanoparticles are efficiently enriched in 4T1 breast cancer cells by virtue of the dual-targeting effect of the ET peptide and the EPR; in combination with photothermal therapy, the chemotherapy effect of PTX is remarkably enhanced, and proliferation, invasion and metastasis of tumor cells are effectively inhibited. Proteomics analysis finds that differential proteins are mainly enriched in motor proteins and ferroptosis pathways after intervention of the targeted nanoparticles, and a core mechanism of collaborative treatment is disclosed. Molecular docking proves that PTX and a key target protein receptor have specific interaction, and the multi-mode synergistic strategy provides an innovative technical platform for overcoming the limitation of traditional chemotherapy and developing an efficient and low-toxicity breast cancer treatment scheme.

The invention discloses a drug-loaded microneedle for synergistically treating tumors and preventing metastasis of the tumors and a preparation method and application thereof.The drug-loaded microneedle uses hyaluronic acid as a matrix to construct a soluble microneedle, superparamagnetic ferroferric oxide nanoparticles are loaded in the soluble microneedle, the ferroferric oxide nanoparticles carry active components, and the drug-loaded microneedle is prepared from the active components. Wherein the active component is a chemotherapeutic drug adriamycin or / and deoxyribonuclease I; under the action of a constant magnetic field, the ferroferric oxide nanoparticles realize magnetic targeting delivery and retention of active components; under an alternating magnetic field, the ferroferric oxide nanoparticles generate a magnetocaloric effect to promote quick release of active components, and tumor cell injury is induced through the magnetocaloric effect; the released chemotherapeutic drug doxorubicin is used for killing tumor cells, the chemotherapeutic drug doxorubicin and the magnetocaloric effect synergistically enhance the chemotherapeutic effect, and the released deoxyribonuclease I is used for degrading an over-expressed neutrophil extracellular trapping net in a tumor microenvironment, so that the microenvironment of tumor metastasis is destroyed.

The invention discloses a preparation method and an application of a biotin modified ultrathin two-dimensional As2Te3 nano material. The preparation method comprises the following steps: performing hydrothermal crystallization on As2Te3 amorphous powder, performing ultrasonic liquid phase stripping to obtain the ultrathin two-dimensional As2Te3 nano material, and finally performing biotin modification to obtain the biotin-modified ultrathin two-dimensional As2Te3 nano material. The biotin-modified ultrathin two-dimensional As2Te3 nano material prepared by the invention has an excellent chemotherapy effect, and can effectively target tumor tissues to realize a tumor inhibition effect; meanwhile, anti-tumor immune response can be activated, tumor growth is inhibited, an excellent anti-tumor treatment effect is achieved, and a new scheme is provided for novel targeted chemotherapy and immunotherapy.

The application discloses application of a vortioxetine and gemcitabine composition in preparation of a drug for resisting pancreatic cancer, and the composition is composed of vortioxetine and gemcitabine. The composition of the application can reduce the expression amount of MAOB protein, promote the apoptosis of pancreatic cancer cells, and synergistically increase the sensitivity of pancreatic cancer cell lines in vitro and pancreatic cancer mice in vivo to gemcitabine, so that the chemotherapy effect of pancreatic cancer cells which are resistant to gemcitabine is significantly improved after treatment by the composition. The composition of the application provides a new chemotherapy drug for pancreatic cancer cells which are resistant to gemcitabine treatment.